Abstract
Inhibition of MAPK signalling can restore sensitivity to radioactive iodine (RI) in patients with radioiodine resistant thyroid cancer. Tramatenib has recently been used to resensitize RI resistant RAS positive or RAS and BRAF negative thyroid carcinomas.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
